Lepu Biopharma Co., Ltd.
2157.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.89B
Close$
Share Statistics
| Market cap | $6.89 Billion |
|---|---|
| Enterprise Value | $7.39 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.14 |
| Beta | -0.42 |
| Outstanding Shares | 1,804,440,000 |
Return
| Return on Equity | 4.65% |
|---|---|
| Return on Assets | 2.08% |
| Return on Invested Capital | -3.93% |
Valuation & Multiples
| P/E Ratio | 24.09 |
|---|---|
| PEG | -68.27 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.41 |
| Enterprise Value to EBIT | -87.62 |
| Enterprise Value to Net Income | 112 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | 0.84 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lepu Biopharma Co., Ltd.
646 employees
CEO: Sui Ziye Lepu Biopharma Co., Ltd. operates as a biopharmaceutical enterprise, concentrating its efforts on the development of innovative oncology therapies. It maintains a broad pipeline of cancer-fighting products primarily aimed at the Chinese ...